Alix Ventures
San Francisco, California · Invests in US · Website
Check size
$100K-$500K
Thesis
Life sciences is experiencing unprecedented innovation through TechBio—companies that merge technology and biology. We partner with passionate, accomplished founders with unique insights to solve daring life science problems and significantly impact patient care. We provide capital, operational support, scientific guidance, and industry relationships to build transformative companies.
Likely not a fit for
Not interested in internationally located companies (outside USA). Avoid single indication diagnostics, single asset therapeutics, medical devices, microbiome, longevity/wellness focus, or non-life-sciences biology. Focus exclusively on TechBio driving patient impact.
How they invest
- Lead or follow
- Leads or follows
- Typical decision
- ~2 weeks
- Warm intro
- Not required
- Involvement
- Advisor
- Fund status
- Actively deploying
- Decision process
- Partnership vote
Partners & team
6 contacts on file
Chas Pulido
Founder & General Partner · Primary contact
Nick Goldner
Venture Partner
Mark Pulido
Operating Partner
Brian Fiske
SAB Member - Drug Development
Daniel Delubac
SAB Member - Diagnostics/Lab Services
Jake Becraft
SAB Member - Syn Bio / CGT
Portfolio
Xilis is an oncology and precision health company focused on cancer diagnosis and treatment using micro-organoids. It develops ex-vivo technologies to accelerate drug discovery and aims to de-risk drug development and guide precision medicine.
Elegen specializes in cell-free clonal gene synthesis through its ENFINIA DNA technology, providing innovative solutions for genetic engineering and synthetic biology.
64x.com offers digital imaging, web hosting, and design services, including posters, banners, and promotional product imprinting.
Mythic is a pioneering AI processor company specializing in analog compute-in-memory technology, which delivers significant improvements in energy efficiency and performance for edge AI applications. Their Analog Matrix Processors enable high-performance computing for various sectors, including automotive, robotics, and defense, while drastically reducing power consumption and costs.
Endpoint Health is a company valued at $150M or more, named in Y Combinator's Top Companies list, and launched to assist hospitals in treating critically ill patients.
Zafrens is pioneering a comprehensive experimental platform that integrates multi-omics and large perturbation libraries to uncover causal relationships in biology. Their technology, Z-Screen, allows for high-throughput experimentation with single-cell resolution, enabling simultaneous phenotypic and molecular screening for drug discovery.
Teiko simplifies cytometry for global clinical trials with innovative products like blood preservation kits and multiparameter flow cytometry services.
Circularis is focused on the cultivation of micro-algae to produce nutritious food and feed ingredients, emphasizing a circular bio-economy and sustainable practices.
Galatea Bio is a biotechnology company focused on leveraging genetic diversity and advanced data analytics to drive innovations in healthcare. They provide clinical testing, genomic services, and biopharma R&D, while emphasizing the importance of underrepresented populations in genetic research.
Basil Systems, also known as basil.bio, focuses on applied AI solutions.
Pair Team is a connected care ecosystem that provides whole-person care by addressing medical, behavioral, and social needs through partnerships with local organizations and AI-enabled technology.
Recent activity
- Oct 2025
iOrganBio
Seed · Participated
- Dec 2024
Endpoint Health
Series A · Lead
- Jun 2024
Zafrens
Seed · Lead
- Mar 2024
Mythic
Seed · Lead
- Sep 2023
Circularis
Seed · Lead
Alix Ventures in the news
Failory
Top 286 Venture Capital Firms in San Francisco (2026)
7 months ago
Meet the 66 rising stars of venture capital, who shook up the industry in 2023
Nov 2023
Chemify raises £36m to fund digital chemistry
Aug 2023
Seven from Notre Dame featured in Forbes 30 Under 30
Jan 2023
Chas Pulido
Jan 2023
Xilis Announces Series A Extension, Bringing Total Round to Over US$89 Million
Jul 2022
Endpoint Health Raises $52 Million in Financing to Expand and Progress Precision Immunology Pipeline
Jun 2022
Cancer treatment startup started by Duke faculty raises $70M
Jul 2021
Biotech startup using AI to take guesswork out of cancer drug selection raises $70M
Jul 2021
Announcing Soma Capital’s Summer 2020 Fellows
Jul 2020
Similar firms
Early-stage TechBio investor focused on platform companies, distinguished by a trademarked TechBio focus and an embedded Fellows program placing MDs, PhDs, and experts as an in-house scientific brain trust. The firm coined and trademarked the term "TechBio" to capture the rise of innovation where technology meets biology. They invest in data-driven life sciences companies that solve problems affecting everyday people from across the globe.
Bioscience investor translating grant-funded research into venture-scale companies, with a pipeline centered on engineering biology using robotic cloud labs and computational design for human health and planetary sustainability. The firm grew directly out of a philanthropic grants program at the Thiel Foundation that funded highly speculative science before spinning into a traditional venture fund.
Flagship Pioneering operates as an "institutional innovation" model that internally originates 80-100 "explorations" per year through Flagship Labs based on "What if…?" hypotheses, then systematically evolves promising ideas through a staged company-creation funnel (Explorations → ProtoCos → NewCos → GrowthCos) that it fully founds, funds, and owns through early stages. The firm positions itself as principal founder rather than a traditional investor, building "bioplatform" companies organized around proprietary discovery engines and operating its own drug development unit, Pioneering Medicines, which partners directly with large pharmas like Pfizer and Novo Nordisk to co-create therapeutics.
Fellowship for early-career scientists run by repeat deep-tech founders, prioritizing technical founder quality, for those who've never written business plans, offering up to $1M and not taking IP rights. SciFounders is run by repeat deep-tech founders who previously built Mammoth Biosciences and Conception. The fund is designed for scientists who have never written a business plan and focuses on technical founder quality over trendy ideas, operating as a long-term partner rather than a fixed-cohort program with no formal end date.
Early-stage accelerator for synthetic biology and life sciences that gives scientist-founders lab independence with co-located BSL-rated wet labs and extended runway via SOSV integration reserving 75% for follow-ons. The world's first startup accelerator focused specifically on synthetic biology and life sciences, created to give scientists independence as founders rather than forcing them into traditional academic or big-pharma tracks. The program runs its own large wet-lab infrastructure where portfolio companies co-locate and build in BSL-rated labs owned by the fund, while providing an unusually long runway of capital through deep integration with SOSV's fund structure that reserves 75% for follow-on rounds.
Research briefRead more
Add Alix Ventures to your investor list
Sign up free to save investors, see partner contacts, and track your raise.
Sign up